Safety study

Why assess safety?

Dietary/Food supplements contain active ingredients that have biological effects in the body. As ingredient manufacturers, we are responsible for making sure our products are safe for the final consumer.

Thus, as we developed this new highly bioavailable turmeric extract formulation to achieve significant pharmacological outcomes, it was crucial for us to ensure full safety of a higher level of curcuminoids in the blood as well as the innocuity of our additional ingredients to guarantee compliance and consumer safety in supplements.

Best in class safety program – What sets us apart?

Because we believe that safety is central, we hold ourselves to the highest standards, which include:

• Conducting the first and only clinical safety trial in healthy volunteers to evaluate the innocuity of our formula while providing a higher dose of curcuminoids in blood
• Testing curcuminoids’ long term impact by assessing a chronic consumption of 5 weeks in healthy subjects
• Following the gold standard process developed by numerous external regulatory authorities worldwide

In vitro and in vivo safety

Because of the ingredient’s increased bioavailability, a single 300 mg serving delivers the same amount of curcuminoids to the blood as 1,922 mg of standard turmeric (containing 95% curcuminoids) to ensure that consumers receive an effective dose.

Safety of this innovative formulation was evaluated using the standard OCDE in vitro genotoxicity tests and in vivo repeated-dose (28‐ and 90‐day) oral toxicity studies in rats (Phipps et al, 2020). In conclusion, the negative results in the in vitro genotoxicity tests, in addition to the absence of any test item‐related adverse effects in the 90‐day study at doses up to 3000 mg/kg body weight/day, support the safe use of Turmipure Gold® for the general population.

Clinical safety study

To complement our in vitro and in vivo results, we chose to go further by performing a unique clinical study in human subjects.

Thus, we conducted, in France, a safety study to assess the innocuity and tolerance of long-term administration of a high dose of Turmipure Gold® (1000mg, hence three times the recommended dose).

Our study was designed as a double-blind randomized placebo-controlled clinical trial to evaluate the chronic safety and tolerance of Turmipure Gold® in healthy subjects during 5 weeks. Sixty healthy volunteers (24 male and 36 female) were enrolled.

Because of the potential effect of high curcuminoid dosage on the gastrointestinal tract, our study specifically assessed the gastrointestinal tolerance of Turmipure Gold®. The primary outcome was a composite score of gastrointestinal tolerance (combined scores for bloating, abdominal cramping, stomach noises, flatulence, and frequency and consistency of stools); secondary outcomes included individual gastrointestinal symptoms and Gastrointestinal Quality of Life (GIQLI), hematology, clinical biochemistry and urinalysis, and a record of adverse events (AEs). There were no statistically significant differences in gastrointestinal tolerance scores or GIQLI. Clinical pathology parameters, vital signs or physical examinations were unaffected by Turmipure Gold® consumption, and the incidence and severity of AEs were similar in both groups. In conclusion, daily oral consumption of Turmipure Gold® (1000 mg) for 5 weeks was well tolerated and safe in healthy adults.